Recently, Anderson et al [1] reported on the generalizability of trials supporting the 2017 American College of Cardiology/American Heart Association blood pressure guideline. They are correct when concluding that SPIRIT and ACCORD, the clinical trials underlying new treatment thresholds, were not representative for more than two-thirds of the target population. Yet, as the authors did [1], in these two sentences two concepts have been used as if they were interchangeable: generalizability and representativeness.
